Pittsburgh

Crucial COVID-19 booster decisions ahead from FDA, CDC – Pittsburgh, Pennsylvania

Pittsburgh, Pennsylvania 2021-09-22 11:16:00 –

A leading advisory board of the Centers for Disease Control and Prevention was convened Wednesday to discuss which Americans should get the COVID-19 booster shot and when. Another advisory group, which serves the Food and Drug Administration, overwhelmingly rejected the White House’s large-scale plan to distribute third shots to almost everyone. Instead, the panel approved a booster dose of Pfizer vaccine only in the elderly and those at high risk of the virus. The COVID-19 vaccine continues to provide strong protection against severe illness, hospitalization, and death. But immunity to mild infections was only the first hurdle when the government set up a booster policy last week’s decision by the FDA Advisory Board. The FDA itself must decide whether to agree with the advisor’s recommendations and approve the Pfizer booster. If you agree, the CDC should recommend who will take additional shots after hearing the feedback from its Immunization Implementation Advisory Board. It will be extended until Thursday. The priority is unvaccinated vaccination, and the CDC states that it accounts for the majority of COVID-19 cases and has soared to levels not seen since last winter. About 182 million Americans are fully vaccinated, accounting for nearly 55% of the total population. Dr. Matthew Daly, a researcher at Kaiser Permanente Colorado and an adviser to the CDC, who held the meeting on Wednesday, said: For example, do healthcare professionals who are continuously exposed to the virus need to qualify as boosters? Another question was how many months after the second injection should the booster be given. Scientists talked about about 6 or 8 months. Many experts are worried about the need for boosters because they have confirmed that the COVID-19 vaccine is working as expected. It is normal for antibodies that fight the virus to decline months after vaccination. Still, the body has backup protection against viruses. Part of the government’s calculation is whether preventing a fully vaccinated “breakthrough” infection can reduce viral infections and protect and facilitate infants who are not yet vaccinated. The overwhelming burden on the medical system. The government will later decide whether to allow additional doses of Moderna or Johnson & Johnson vaccines. The Associated Press Health and Science Department is supported by the Science Education Department of the Howard Hughes Medical Institute. AP is solely responsible for all content.

A leading advisory board of the Centers for Disease Control and Prevention was convened Wednesday to discuss which Americans should receive the COVID-19 booster shot and when. This is a more controversial question than the Biden administration had clearly expected.

The meeting took place a few days after another advisory group, which serves the Food and Drug Administration, overwhelmingly rejected the large-scale White House plan to distribute third shots to almost everyone. I did. Instead, the panel approved a booster dose of Pfizer vaccine only for the elderly and those at high risk for the virus.

The COVID-19 vaccine continues to provide strong protection against severe illness, hospitalization and death, but immunity to mild infections appears to be diminished months after vaccination.

Last week’s FDA Advisory Board decision was only the first hurdle when the government set up a booster policy. The FDA itself must decide whether to agree with the advisor’s recommendations and approve the Pfizer booster.

If so, the CDC must recommend who should take additional shots after hearing from the Immunization Implementation Advisory Board, where the meeting was scheduled to be extended on Thursday.

The priority remains unvaccinated, and the CDC states that it accounts for the majority of COVID-19 cases and has skyrocketed to levels not seen since last winter. About 182 million Americans are fully vaccinated, accounting for nearly 55% of the total population.

Dr. Matthew Daly, a researcher at Kaiser Permanente, Colorado, said: CDC advisor who held a meeting on Wednesday.

Much of the discussion at the meeting was expected to be about who is considered to be at high enough risk for additional doses. For example, whether health care workers who are continuously exposed to the virus need to qualify for booster immunization.

Another question was whether to give a booster months after the second shot. Scientists talked for about 6 or 8 months.

Many experts are worried about the need for boosters because they believe the COVID-19 vaccine is working as expected. It is normal for antibodies that fight the virus to decline months after vaccination. Still, the body has backup protection against viruses.

Part of the government’s calculations is that preventing fully vaccinated “breakthrough” infections will reduce viral infections, protect infants who are not yet vaccinated, and burden the overwhelming medical system. Whether it helps to mitigate.

The government will later decide whether to allow additional doses of Moderna or Johnson & Johnson vaccines.

___

The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.

Crucial COVID-19 booster decisions ahead from FDA, CDC Source link Crucial COVID-19 booster decisions ahead from FDA, CDC

Back to top button